Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1 Building on its leadership in colorectal cancer screening with the Cologuard® test, Abbott is connecting innovations across the cancer care...